Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the aphrodite data

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 4, 2008, Pages 233-237

  Cassano, N ^a   Galluccio, A ^b   De Simone, C ^c   Loconsole, F ^a   Massimino, S D ^d   Plumari, A ^d   Dattola, S ^e   Guerra, A Puglisi ^f   Donato, L ^g   Cantoresi, F ^h   De Pita O ⁱ   Fenizi, G ^j   Altamura, V ^k   Congedo, M ^l   Pellicano, R ^m   Vena, G A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Sacro Cuore Hospice   (Italy)

^d GARIBALDI HOSPITAL   (Italy)

^e Melito Porto Salvo   (Italy)

^f Papardo Hospital   (Italy)

^g Crotone Hospital   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k PERRINO HOSPITAL   (Italy)

^l VITO FAZZI HOSPITAL   (Italy)

^m CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

more..

Author keywords

Adalimumab; Blood hypertension; Body mass index; Metabolic comorbidities; Psoriasis; Response

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANAMNESIS; ARTICLE; BIOLOGICAL THERAPY; BODY MASS; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PSORIASIS; PSORIASIS SEVERITY INDEX; SYSTEMIC THERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; BODY MASS INDEX; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

APHRODITA;

EID: 58149350282     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55:598-606.
2. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106-15.
3. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-66.
4. Vena GA, Galluccio A, De Simone C, et al. A multicenter open-label experience on the response of psoriasis to adalimumab and effect of dose escalation in non-responders: the APHRODITE project. Int J Immunopathol Pharmacol, (submitted).
5. Strober B, Gottlieb AB, Johnson R, Leonardi C, Papp K. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol 2006; 54 (S3):abstr P2890.
6. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Rev Dermatol 2007; 2:335-49.
7. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58:443-6.
8. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol (Paris) 2006; 54: 375-86.
9. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157:68-73.
10. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, Marchegiani F, Offidani A. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopatbol Pharmacol 2007; 20:731-6.
11. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19:5-21.
12. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008; 7:373-7.
13. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455:221-5.